Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
- Conditions
- Mild Spinal Tuberculosis
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 300
- Registration Number
- NCT06917495
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, China
A PAN-USR TB Multi-Center Trial
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen Third People's Hospital
- Target Recruit Count
- 610
- Registration Number
- NCT06905522
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Tuberculosis, Lymph NodeMycobacterium TuberculosisTuberculosisTuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇧🇼
12701, Gaborone CRS, Gaborone, Botswana
🇧🇷12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil
🇧🇷12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- 🇿🇦
TASK Eden, George, South Africa
🇹🇿NIMR Mbeya, Mbeya, Tanzania
🇿🇦TASK Brooklyn, Cape Town, South Africa
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Pulmonary TuberculosisRifampicin-resistant Tuberculosis
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China
🇨🇳People's Hospital of Linyi, Linyi, China
🇨🇳Fourth People's Hospital of Nanning, Nanning, China
Intensified Short Course Regimen for TBM in Adults
- Conditions
- Tuberculous Meningitis
- Interventions
- Drug: High dose rifampicin (25mg/kg)Drug: HRZEDrug: HREDrug: Steroid
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 372
- Registration Number
- NCT05917340
- Locations
- 🇮🇳
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India
PanACEA - STEP2C -01
- Conditions
- Other Specified Pulmonary TuberculosisPulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Tuberculosis, PulmonaryHIV
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.